Sepsis-related degradation of the endothelial glycocalyx (eGCX) was the central pathophysiological target in the reviewed literature. The authors summarized interventions that investigators have tested to preserve or restore the eGCX across experimental and clinical settings. The review captured a diverse set of candidate therapies: ascorbic acid, sulodexide, doxycycline, activated protein C, heparin-based therapies, antithrombin, recombinant thrombomodulin, therapeutic plasma exchange, colivelin, liposomal nanocarriers of preassembled eGCX, and rhamnan sulfate. Some agents were repurposed drugs with known anticoagulant or anti-inflammatory properties; others were experimental biologics or novel delivery platforms. The abstract did not report dosing regimens, timing of administration, or comparative efficacy rankings among agents. Investigators reported that several interventions produced reductions in indices of eGCX shedding in their respective models.
The systematic review restricted eligible outcomes to metrics directly linked to eGCX integrity. Circulating biomarkers featured prominently: syndecan-1, heparan sulfate and hyaluronan were cited as commonly measured indicators of eGCX shedding. Microcirculatory assessment included the perfused boundary region, a device-derived metric sensitive to glycocalyx thickness. Structural assessment of the eGCX was captured by microscopy-based techniques in selected studies. The authors noted these outcome domains—biochemical markers, microvascular function, and ultrastructural imaging—without providing pooled quantitative data in the abstract. The review therefore characterizes the outcome landscape but does not present standardized effect estimates across interventions.
Seventeen of the 21 included studies were animal experiments. Within those preclinical reports, investigators observed that multiple interventions reduced biochemical markers of eGCX breakdown and improved measures of endothelial barrier or microvascular function. A subset of animal studies reported preservation or restoration of eGCX ultrastructure on microscopy after intervention. The abstract attributes these positive signals to various agents but does not enumerate study-by-study effect sizes, animal species, or model-specific endpoints. Readers should interpret the preclinical signals as hypothesis-generating—evidence that interventions can modulate eGCX-related measures under experimental conditions, rather than definitive proof of clinical benefit in human sepsis.
Only four human studies met the review’s inclusion criteria. The review team observed that clinical data remain sparse compared with the volume of preclinical work. The abstract did not report patient numbers, trial design details, primary clinical endpoints, or numeric biomarker changes from those human investigations. Investigators therefore conclude that while eGCX-directed strategies have biological plausibility and preclinical support, translation to routine clinical practice is premature given the limited and heterogeneous human evidence base.
The authors assessed risk of bias using established tools: RoB 2 for randomized trials, SYRCLE for animal studies, and ROBINS-I for non-randomized studies. The abstract confirms that risk-of-bias assessment was performed but does not disclose aggregated scores or domain-specific findings in the summary. Methodological heterogeneity was evident across included studies—differences in species and models, outcome measures (biomarkers versus imaging), and intervention types—making direct comparison difficult. The review accordingly frames the current literature as varied in design and quality, and it signals the need for standardized outcome definitions and harmonized methodology in future work.
The review’s primary limitation, as stated by the authors, is the preponderance of preclinical data: most evidence for eGCX-directed therapies in sepsis remains experimental. Human studies were few and were not described in detail within the abstract. The authors registered their protocol in PROSPERO (CRD420251270767) and declared no conflicts of interest. They recommend that well-designed clinical studies with standardized eGCX outcome measures are required to determine whether reductions in biomarkers or improved microcirculation translate into meaningful clinical benefits for patients with sepsis. The abstract did not specify which trial designs, sample sizes, or primary clinical endpoints would be optimal, nor did it provide timelines for such studies.
Limitations documented in the source: most evidence remains preclinical, human data are limited to four studies, and the abstract lacks study-level numeric outcomes and dosing details. The next steps identified by the authors are the conduct of standardized, rigorous clinical trials to test whether eGCX-targeted interventions improve patient-centered outcomes in sepsis.